Estradiol pivalate/progesterone

Last updated
Estradiol pivalate/progesterone
Estradiol pivalate structure.svg
Progesterone.svg
Estradiol pivalate (top) and
progesterone (bottom)
Combination of
Estradiol pivalate Estrogen
Progesterone Progestogen
Clinical data
Trade names Estrotate with Progesterone
Other namesETMA/P4; EP/P4
Routes of
administration 		Intramuscular injection

Estradiol pivalate/progesterone (ETMA/P4), sold under the brand name Estrotate with Progesterone, is a combination medication of estradiol pivalate (estradiol trimethylacetate; ETMA), an estrogen, and progesterone (P4), a progestogen, which was used in menopausal hormone therapy and the treatment of gynecological disorders but is no longer available. [1] [2] [3] It contained 1 mg/mL ETMA and 10 mg/mL P4 in oil solution provided in vials and was administered by intramuscular injection at regular intervals. [1] [2] [3]

ETMA/P4 was introduced for medical use by 1949. [1] [2] [3] It was one of the first combined estrogen and progestogen medications to be marketed, and was followed by the more well-known estradiol benzoate/progesterone (brand name Duogynon) in 1950. [4] Other similar estrogen–progestogen preparations were also subsequently introduced. [4]

See also

References

  1. 1 2 3 "New Drugs and Instruments" . Postgraduate Medicine. 5 (5): 434–436. May 1949. doi:10.1080/00325481.1949.11693827. ESTROTATE AND ESTROTATE WITH PROGESTERONE purpose: Steroid hormone therapy. composition: Estrotate is the trimethyl acetic acid ester of alpha-estradiol. indications for use: Control of menopausal syndrome, functional uterine [...]
  2. 1 2 3 Howard ME (1949). Modern Drug Encyclopedia and Therapeutic Index. Drug Publications. [...] Supply: ESTROTATE—Vials, multi dose 10 cc. Combination: ESTROTATE WITH PROGESTERONE—Each cc contains 1 mg estradiol trimethyl acetate and 10 mg progesterone. For the simultaneous administration where both natural ovarian [...]
  3. 1 2 3 Tyler ET (1949). "Use and misuse of endocrine therapy in sterility". Journal of the American Medical Association. 139 (9): 560–4. doi:10.1001/jama.1949.02900260006002. ISSN   0002-9955. PMID   18123546. Both hormones may be given in one injection with a preparation which contains 10 mg. of progesterone and 1 mg. of [estradiol] trimethyl acetate per cubic centimeter.15 One cubic centimeter is given three times weekly. [...] Supplied as Estrotate® (trimethyl acetic acid ester of alpha [estradiol] in sesame oil) with progesterone.
  4. 1 2 Kaiser R (2008). "Gestagen-Östrogen-Kombinationen in der Gynäkologie. Zur Geschichte, Dosierung und Anwendung eines Hormonprinzips" [Progestogen-Estrogen Combinations in Gynecology. History, Dosage, and Use of a Hormone Principle]. Geburtshilfe und Frauenheilkunde. 53 (7): 503–513. doi:10.1055/s-2007-1022924. ISSN   0016-5751. PMID   8370495. Zur kombinierten Anwendung von Gestagen en und Östrogenen stand en zunächst ölgelöstes Östradiolbenzoat und Progesteron zur Verfügung. Das erste derartige Mischpräparat kam in Deutschland 1950 auf den Mark t. Dem Wunsch nach verlän gerter Wirkungsdauer entsprach en dann Kristallmischsuspension en verschiedener Korngröße aus Östradiolmonobenzoat + Progesteron, deren Anwendung sich auf klinische Untersuchungen besch ränkte (83). Ölgelöste Depotpräparate mit Östradiolbenzoat oder -valerat + 17-hydroxyprogesteroncaproat wurden ab 1955 in die Therapie eingeführt (45.46).


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.